IP Library Granted Patent US 8,575,362
Granted Patent B2
US 8,575,362 · App. 13/160,678 · Granted Nov 5, 2013

Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,575,362
App. No.
13/160,678
Granted
Nov 5, 2013
Kind
B2
Abstract

Methods useful for preparing compounds of formula I: and salts thereof are disclosed. Also disclosed are intermediates useful in the preparation of such compounds.

Claims (14)

1. A method of preparing a compound of formula II(a):

which comprises Noyori hydrogenation of a compound of formula IV:

with a platinum group metal catalyst having a Noyori-type chiral ligand, wherein:

A 1 is pyrazole;

R 1 is chloro; and

m is 1.

2. The method of claim 1 , wherein the chiral ligand is (1R,2R)-(−)-N-(4-toluenesulfonyl)-1,2-diphenylethylenediamine or N-((1R,2R)-2-aminocyclohexyl)-4-methylbenzenesulfonamide).

3. The method of claim 1 , wherein the platinum group metal catalyst is dichloro(pentamethylcyclopentadienyl)iridium (III) dimer.

4. The method of claim 1 , wherein the compound of formula IV is prepared by reacting 1-(2-bromo-5-chlorophenyl)-3-methyl-1H-pyrazole with a trifluoroacetylating agent under transmetalation conditions.

5. The method of claim 4 , wherein the trifluoroacetylating agent is ethyl trifluoroacetate.

6. The method of claim 4 , wherein the transmetalation conditions comprise the use of an alkyllithium or alkylmagnesium reagent.

7. The method of claim 6 , wherein the alkyllithium reagent is n-butyllithium, sec-butyllithium, or t-butyllithium.

8. The method of claim 6 , wherein the alkylmagnesium reagent is isopropyl magnesium chloride or tributylmagnesium chloride.

9. The method of claim 1 , wherein the compound of formula II(a) is crystalline (R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethanol.

Assignments (11)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS AT R/F 41939/0487, 46591/0544 AND 53940/0001 Recorded Apr 15, 2026
From: MIDCAP FINANCIAL TRUST
To: TERSERA THERAPEUTICS LLC,
Reel/Frame 075420/0453 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT R/F 63227/0852 Recorded Jan 7, 2025
From: NEWSTONE CAPITAL PARTNERS, LLC
To: TERSERA THERAPEUTICS LLC
Reel/Frame 069835/0704 →
SECURITY INTEREST Recorded Apr 5, 2023
From: TERSERA THERAPEUTICS LLC
To: NEWSTONE CAPITAL PARTNERS, LLC
Reel/Frame 063227/0852 →
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2023
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: TERSERA THERAPEUTICS LLC
Reel/Frame 063253/0942 →
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2023
From: NEWSTONE CAPITAL PARTNERS, LLC
To: TERSERA THERAPEUTICS LLC; JDP THERAPEUTICS LLC
Reel/Frame 063221/0546 →
SECURITY INTEREST Recorded Apr 4, 2023
From: TERSERA THERAPEUTICS LLC
To: ANTARES CAPITAL LP, AS AGENT
Reel/Frame 063215/0724 →
SECURITY INTEREST Recorded Sep 30, 2020
From: TERSERA THERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 053940/0001 →
RELEASE OF SECURITY INTEREST Recorded Sep 14, 2020
From: BIOPHARMA CREDIT PLC
To: LEXICON PHARMACEUTICALS, INC.
Reel/Frame 053767/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: LEXICON PHARMACEUTICALS, INC.
To: TERSERA THERAPEUTICS LLC
Reel/Frame 053763/0754 →
SECURITY INTEREST Recorded Sep 9, 2020
From: TERSERA THERAPEUTICS LLC
To: NEWSTONE CAPITAL PARTNERS, LLC
Reel/Frame 053721/0037 →
SECURITY INTEREST Recorded Dec 20, 2017
From: LEXICON PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 044958/0377 →